91Ó°ÊÓ

All drugs must be approved by the U.S. Food and Drug Administration (FDA) before they can be marketed by a drug company. The FDA must weigh the error of marketing an ineffective drug, with the usual risks of side effects, against the consequences of not allowing an effective drug to be sold. Suppose, using standard medical treatment, that the mortality rate \((r)\) of a certain disease is known to be \(A .\) A manufacturer submits for approval a drug that is supposed to treat this disease. The FDA sets up the hypothesis to test the mortality rate for the drug as \((1) H_{o}: r=A, H_{a}: rA, \alpha=0.005\) a. If \(A=0.95,\) which test do you think the FDA should use? Explain. b. If \(A=0.05,\) which test do you think the FDA should use? Explain.

Step by step solution

01

Determine Hypothesis Based on Mortality Rate A = 0.95

When \(A=0.95\) (95%), the mortality rate is high. Here, the FDA would be interested in seeing if the new drug can decrease this high mortality rate. If the mortality rate remains at 95% or increases, the drug would not be effective. Therefore, the FDA should use the hypothesis \(H_{o}: r=A, H_{a}: r<A, \alpha=0.005\). Here, the null hypothesis is that the mortality rate is 95% but the FDA hopes that the drug can prove the alternative hypothesis true, that the mortality rate is less than 95%.

02

Determine Hypothesis Based on Mortality Rate A = 0.05

When \(A=0.05\) (5%), the mortality rate is low. In this case, the FDA would want to check that the new drug is not increasing this low mortality rate. If the mortality rate remains at 5% or decreases, the drug could be considered effective. Hence, the FDA should use the hypothesis \(H_{o}: r=A, H_{a}: r>A, \alpha=0.005\). Here, the null hypothesis is that the mortality rate is 5% with a hope that the drug can keep it low and not prove the alternative hypothesis, that the mortality rate is more than 5%.

Unlock Step-by-Step Solutions & Ace Your Exams!

• Full Textbook Solutions

  Get detailed explanations and key concepts

• Unlimited Al creation

  Al flashcards, explanations, exams and more...

• Ads-free access

  To over 500 millions flashcards

• Money-back guarantee

  We refund you if you fail your exam.

Over 30 million students worldwide already upgrade their learning with 91Ó°ÊÓ!

Key Concepts

These are the key concepts you need to understand to accurately answer the question.

FDA Approval Process

The FDA approval process is crucial for ensuring the safety and efficacy of drugs before they reach the market. Every drug must undergo rigorous testing and evaluation. This process protects the public from potentially harmful or ineffective medications.

Here is a simplified overview of the FDA approval process:

• Preclinical Testing: Before testing on humans, a drug undergoes laboratory and animal testing to evaluate its safety and biological activity.
• Clinical Trials: These are conducted in multiple phases.
  • Phase 1 focuses on safety and involves a small number of healthy volunteers.
  • Phase 2 expands to assess effectiveness and further safety studies in a larger group.
  • Phase 3 involves even more participants to confirm effectiveness, monitor side effects, and collect data for safe usage.
• FDA Review: After successful trials, the pharmaceutical company submits a New Drug Application (NDA) for FDA review. This review involves analyzing study results, labeling, and proposed manufacturing processes.
• Approval or Denial: The FDA will approve the drug if the benefits outweigh the risks, ensuring it is safe for public consumption.

This process ensures medications are thoroughly examined before they are available to consumers, reducing risks associated with new drugs.

Mortality Rate

The mortality rate is a key parameter when evaluating the potential impact of a new drug. It represents the proportion of deaths in a population over a specific period.

Understanding this rate helps the FDA assess how effective a new treatment is in improving patient outcomes.

Here's how it relates to drug approval:

• High Mortality Rate: When dealing with diseases that have a high mortality rate, even a slight improvement due to a new drug can be significant. The focus would be on determining if the drug can reduce the mortality rate.
• Low Mortality Rate: With diseases that already have a low mortality rate, new drugs are scrutinized to ensure they don't inadvertently increase this rate and remain beneficial.

In either situation, accurate and precise data on mortality rates allow the FDA to make informed decisions about potential drug approvals.

Type I and Type II Errors

In hypothesis testing, particularly in the FDA approval context, understanding Type I and Type II errors is fundamental. These errors influence decisions on whether to approve or deny a new drug.

Let's break down these concepts:

• Type I Error (α): Occurs when a true null hypothesis is incorrectly rejected. In the context of drug approval, this might mean approving a drug that actually isn't effective. Minimizing Type I errors is critical, which is why a low significance level (e.g., 0.005) is often used.
• Type II Error (β): Happens when a false null hypothesis is not rejected. This can lead to missing out on a potentially effective drug because the analysis fails to detect its real benefit. Balancing this type of error involves ensuring tests are sensitive enough to identify real effects.

Both error types have serious implications:

• Type I errors could expose the public to ineffective or harmful treatments.
• Type II errors could delay beneficial drugs from reaching patients in need.

A thorough understanding and management of these errors make the FDA approval process robust and reliable, aiming to ensure patient safety while providing access to effective drugs.